Dynavax Technologies Co. (NASDAQ:DVAX) VP David Louis Johnson sold 3,092 shares of Dynavax Technologies stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the transaction, the vice president now directly owns 7,780 shares of the company’s stock, valued at $144,708. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of Dynavax Technologies Co. (NASDAQ:DVAX) traded up $0.50 during trading hours on Friday, hitting $18.50. 836,843 shares of the company’s stock were exchanged, compared to its average volume of 898,000. Dynavax Technologies Co. has a 1-year low of $3.70 and a 1-year high of $24.45. The stock has a market cap of $1,120.00, a PE ratio of -9.44 and a beta of 1.31.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.28 million. During the same period in the previous year, the company earned ($0.90) EPS. The firm’s revenue for the quarter was down 68.8% compared to the same quarter last year. analysts forecast that Dynavax Technologies Co. will post -1.72 earnings per share for the current year.
DVAX has been the subject of a number of recent research reports. Cowen reissued a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 3rd. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective for the company. BidaskClub cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 price objective (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Finally, ValuEngine raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Dynavax Technologies has an average rating of “Buy” and an average price target of $25.17.
TRADEMARK VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/05/david-louis-johnson-sells-3092-shares-of-dynavax-technologies-co-dvax-stock.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.